JP Morgan Chase’s Avanos Medical AVNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,099,770
Closed -$27.4M – 8255
2026
Q2
$27.4M Buy
1,099,770
+848,608
+338% +$19.9M ﹤0.01% 1962
2026
Q1
$3.45M Sell
251,162
-22,556
-8% -$304K ﹤0.01% 3678
2025
Q4
$3.07M Sell
273,718
-304,171
-53% -$3.48M ﹤0.01% 3754
2025
Q3
$6.68M Buy
577,889
+311,317
+117% +$3.65M ﹤0.01% 3120
2025
Q2
$3.26M Sell
266,572
-84,033
-24% -$1.06M ﹤0.01% 3548
2025
Q1
$5.02M Buy
350,605
+148,971
+74% +$2.33M ﹤0.01% 3169
2024
Q4
$3.21M Buy
201,634
+132,063
+190% +$2.61M ﹤0.01% 3781
2024
Q3
$1.67M Buy
69,571
+4,472
+7% +$102K ﹤0.01% 4151
2024
Q2
$1.3M Sell
65,099
-62,019
-49% -$1.21M ﹤0.01% 4115
2024
Q1
$2.53M Sell
127,118
-76,110
-37% -$1.47M ﹤0.01% 3673
2023
Q4
$4.56M Hold
203,228
– – ﹤0.01% 3190
2023
Q3
$5.01M Buy
247,539
+131,222
+113% +$2.97M ﹤0.01% 2863
2023
Q2
$2.97M Buy
116,317
+13,497
+13% +$355K ﹤0.01% 3271
2023
Q1
$3.06M Buy
102,820
+9,481
+10% +$275K ﹤0.01% 3219
2022
Q4
$2.53M Sell
93,339
-724
-0.8% -$17.7K ﹤0.01% 3403
2022
Q3
$2.05M Sell
94,063
-161,086
-63% -$4.21M ﹤0.01% 3454
2022
Q2
$6.98M Buy
255,149
+175,806
+222% +$5.05M ﹤0.01% 2487
2022
Q1
$2.66M Buy
79,343
+29,216
+58% +$941K ﹤0.01% 3543
2021
Q4
$1.74M Buy
50,127
+2,470
+5% +$79.9K ﹤0.01% 3968
2021
Q3
$1.49M Sell
47,657
-2,409
-5% -$81.7K ﹤0.01% 4015
2021
Q2
$1.82M Sell
50,066
-169,065
-77% -$6.99M ﹤0.01% 3868
2021
Q1
$9.6M Buy
219,131
+111,415
+103% +$5.23M ﹤0.01% 2407
2020
Q4
$4.94M Sell
107,716
-10,972
-9% -$457K ﹤0.01% 2835
2020
Q3
$3.92M Buy
118,688
+63,186
+114% +$2.02M ﹤0.01% 2768
2020
Q2
$1.63M Buy
55,502
+1,703
+3% +$49.3K ﹤0.01% 3249
2020
Q1
$1.45M Sell
53,799
-7,107
-12% -$212K ﹤0.01% 3198
2019
Q4
$2.05M Sell
60,906
-200,753
-77% -$7.27M ﹤0.01% 3386
2019
Q3
$9.8M Buy
261,659
+96,226
+58% +$3.67M ﹤0.01% 2166
2019
Q2
$7.23M Sell
165,433
-835
-0.5% -$35.7K ﹤0.01% 2369
2019
Q1
$7.1M Buy
166,268
+60,310
+57% +$2.7M ﹤0.01% 2338
2018
Q4
$4.75M Buy
105,958
+47,002
+80% +$2.46M ﹤0.01% 2624
2018
Q3
$4.04M Buy
58,956
+30,414
+107% +$1.96M ﹤0.01% 2936
2018
Q2
$1.63M Sell
28,542
-171,538
-86% -$9.06M ﹤0.01% 3571
2018
Q1
$9.22M Sell
200,080
-644,760
-76% -$30.6M ﹤0.01% 2108
2017
Q4
$39M Buy
844,840
+39,846
+5% +$1.83M 0.01% 1126
2017
Q3
$36.7M Sell
804,994
-73,564
-8% -$3.14M 0.01% 1105
2017
Q2
$34.5M Buy
878,558
+169,194
+24% +$6.39M 0.01% 1113
2017
Q1
$27M Buy
709,364
+15,142
+2% +$590K 0.01% 1277
2016
Q4
$25.7M Buy
694,222
+85,957
+14% +$3.07M 0.01% 1307
2016
Q3
$21.1M Buy
608,265
+532,677
+705% +$18.7M 0.01% 1337
2016
Q2
$2.46M Sell
75,588
-2,508
-3% -$76.8K ﹤0.01% 2719
2016
Q1
$2.24M Sell
78,096
-2,763
-3% -$73.6K ﹤0.01% 2654
2015
Q4
$2.7M Buy
80,859
+1,012
+1% +$31.5K ﹤0.01% 2618
2015
Q3
$2.27M Sell
79,847
-47,134
-37% -$1.64M ﹤0.01% 2693
2015
Q2
$5.14M Sell
126,981
-211,636
-63% -$9.5M ﹤0.01% 2387
2015
Q1
$16.7M Buy
338,617
+282,462
+503% +$13.1M ﹤0.01% 1571
2014
Q4
$2.55M Sell
56,155
-393,724
-88% -$15.5M ﹤0.01% 2842

Other funds holding AVNS

JP Morgan Chase's AVNS Position: Q3 2026 in Review

JP Morgan Chase sold out of Avanos Medical (AVNS) in Q3 2026, closing a stake of 1,099,770 shares — an estimated $27.4M sold.

JP Morgan Chase first reported a position in AVNS in Q4 2014 and held it in 47 quarters. The position peaked at $39M in Q4 2017. 3 funds tracked by Wall St. Rank hold AVNS as of Q3 2026.

  • JP Morgan Chase reported no remaining Avanos Medical position as of Q3 2026 after selling out during the quarter.
  • JP Morgan Chase sold 1,099,770 Avanos Medical shares in Q3 2026, an estimated $27.4M.
  • JP Morgan Chase first reported a position in Avanos Medical in Q4 2014 and held it in 47 quarters.
  • JP Morgan Chase's Avanos Medical position peaked at $39M in Q4 2017.
  • 3 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.